2026-04-27T01:59:30Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/179292024-02-10T20:02:27Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16961

00925njm 22002777a 4500 dc Díaz-Redondo, Tamara author Lavado-Valenzuela, Rocio author Jimenez, Begoña author Pascual, Tomas author Gálvez, Fernando author Falcón, Alejandro author Alamo, Maria Del Carmen author Morales, Cristina author Amerigo, Marta author Pascual, Javier author Sanchez-Muñoz, Alfonso author González-Guerrero, Macarena author Vicioso, Luis author Laborda, Aurora author Ortega, Maria Victoria author Perez, Lidia author Fernandez-Martinez, Aranzazu author Chic, Nuria author Jerez, Jose Manuel author Alvarez, Martina author Prat, Aleix author Ribelles, Nuria author Alba, Emilio author 2019-11-05 Background: Double blockade with pertuzumab and trastuzumab combined with chemotherapy is the standard neoadjuvant treatment for HER2-positive early breast cancer. Data derived from clinical trials indicates that the response rates differ among intrinsic subtypes of breast cancer. The aim of this study is to determine if these results are valid in real-world patients. Methods: A total of 259 patients treated in eight Spanish hospitals were included and divided into two cohorts: Cohort A (132 patients) received trastuzumab plus standard neoadjuvant chemotherapy (NAC), and Cohort B received pertuzumab and trastuzumab plus NAC (122 patients). Pathological complete response (pCR) was defined as the complete disappearance of invasive tumor cells. Assignment of the intrinsic subtype was realized using the research-based PAM50 signature. Results: There were more HER2-enriched tumors in Cohort A (70 vs. 56%) and more basal-like tumors in Cohort B (12 vs. 2%), with similar luminal cases in both cohorts (luminal A 12 vs. 14%; luminal B 14 vs. 18%). The overall pCR rate was 39% in Cohort A and 61% in Cohort B. Better pCR rates with pertuzumab plus trastuzumab than with trastuzumab alone were also observed in all intrinsic subtypes (luminal PAM50 41 vs. 11.4% and HER2-enriched subtype 73.5 vs. 50%) but not in basal-like tumors (53.3 vs. 50%). In multivariate analysis the only significant variables related to pCR in both luminal PAM50 and HER2-enriched subtypes were treatment with pertuzumab plus trastuzumab (Cohort B) and histological grade 3. Conclusions: With data obtained from patients treated in clinical practice, it has been possible to verify that the addition of pertuzumab to trastuzumab and neoadjuvant chemotherapy substantially increases the rate of pCR, especially in the HER2-enriched subtype but also in luminal subtypes, with no apparent benefit in basal-like tumors. 2234-943X http://hdl.handle.net/10668/14717 http://hdl.handle.net/20.500.12105/17929 31750258 10.3389/fonc.2019.01178 Frontiers in oncology Breast cancer Neoadjuvant Pertuzumab Real-world data Trastuzumab Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.